First Interstate Bank Has $1.41 Million Stake in Johnson & Johnson $JNJ

First Interstate Bank trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% in the second quarter, HoldingsChannel reports. The firm owned 9,258 shares of the company’s stock after selling 460 shares during the period. First Interstate Bank’s holdings in Johnson & Johnson were worth $1,414,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Ellis Investment Partners LLC raised its position in shares of Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares during the last quarter. Cypress Wealth Services LLC raised its position in shares of Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after acquiring an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN raised its position in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after acquiring an additional 64 shares during the last quarter. Global Strategic Investment Solutions LLC raised its position in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares during the last quarter. Finally, JSF Financial LLC raised its position in shares of Johnson & Johnson by 2.2% during the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after acquiring an additional 65 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.9%

Shares of Johnson & Johnson stock opened at $191.93 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The business has a fifty day simple moving average of $181.27 and a 200 day simple moving average of $165.37. The stock has a market cap of $462.23 billion, a PE ratio of 18.53, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Bank of America boosted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $200.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.